 Warren Capell
Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rivaroxaban | 15 | 2024 | 253 | 2.470 |
Why?
| | Peripheral Arterial Disease | 16 | 2024 | 474 | 2.020 |
Why?
| | Aspirin | 13 | 2024 | 385 | 1.620 |
Why?
| | Factor Xa Inhibitors | 8 | 2024 | 171 | 1.540 |
Why?
| | Lower Extremity | 12 | 2024 | 427 | 1.460 |
Why?
| | Endovascular Procedures | 5 | 2022 | 315 | 0.870 |
Why?
| | Platelet Aggregation Inhibitors | 11 | 2024 | 460 | 0.790 |
Why?
| | Beneficence | 1 | 2021 | 16 | 0.700 |
Why?
| | Hypertriglyceridemia | 3 | 2006 | 39 | 0.690 |
Why?
| | Research Subjects | 1 | 2021 | 42 | 0.690 |
Why?
| | Thrombosis | 2 | 2022 | 368 | 0.680 |
Why?
| | Personal Autonomy | 1 | 2021 | 48 | 0.680 |
Why?
| | Informed Consent | 2 | 2021 | 170 | 0.670 |
Why?
| | Ischemia | 6 | 2024 | 408 | 0.640 |
Why?
| | Patient Selection | 2 | 2021 | 691 | 0.630 |
Why?
| | Outpatients | 1 | 2021 | 393 | 0.550 |
Why?
| | Venous Thromboembolism | 3 | 2023 | 313 | 0.430 |
Why?
| | Double-Blind Method | 8 | 2024 | 1987 | 0.410 |
Why?
| | Drug Therapy, Combination | 8 | 2024 | 1060 | 0.390 |
Why?
| | Lipoprotein Lipase | 2 | 2010 | 59 | 0.380 |
Why?
| | Lipoproteins | 4 | 2010 | 168 | 0.380 |
Why?
| | Hospitalization | 2 | 2021 | 2197 | 0.370 |
Why?
| | Risk Assessment | 1 | 2021 | 3439 | 0.360 |
Why?
| | Hypolipidemic Agents | 3 | 2006 | 92 | 0.350 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2010 | 30 | 0.340 |
Why?
| | Coronary Artery Disease | 2 | 2024 | 703 | 0.280 |
Why?
| | Hemorrhage | 5 | 2023 | 723 | 0.260 |
Why?
| | Triglycerides | 3 | 2010 | 525 | 0.260 |
Why?
| | Vascular Surgical Procedures | 3 | 2024 | 300 | 0.230 |
Why?
| | Glucose | 1 | 2010 | 1018 | 0.230 |
Why?
| | Myocardial Infarction | 2 | 2022 | 1045 | 0.220 |
Why?
| | Middle Aged | 16 | 2024 | 33355 | 0.210 |
Why?
| | Fatty Acids, Nonesterified | 3 | 2010 | 159 | 0.210 |
Why?
| | Male | 22 | 2024 | 67718 | 0.200 |
Why?
| | Fenofibrate | 1 | 2003 | 29 | 0.200 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2023 | 84 | 0.200 |
Why?
| | Antifibrinolytic Agents | 1 | 2023 | 51 | 0.200 |
Why?
| | Treatment Outcome | 9 | 2024 | 10821 | 0.190 |
Why?
| | Muscle, Skeletal | 2 | 2010 | 1701 | 0.190 |
Why?
| | Multicenter Studies as Topic | 2 | 2021 | 308 | 0.190 |
Why?
| | Humans | 31 | 2024 | 137514 | 0.180 |
Why?
| | Blood Coagulation Disorders | 1 | 2023 | 173 | 0.180 |
Why?
| | Female | 20 | 2024 | 73162 | 0.180 |
Why?
| | Drug-Eluting Stents | 1 | 2021 | 81 | 0.180 |
Why?
| | Postoperative Complications | 2 | 2024 | 2641 | 0.180 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2021 | 105 | 0.170 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2021 | 66 | 0.170 |
Why?
| | Placebos | 1 | 2021 | 207 | 0.170 |
Why?
| | Paclitaxel | 1 | 2021 | 231 | 0.170 |
Why?
| | Clinical Trials as Topic | 3 | 2021 | 1047 | 0.170 |
Why?
| | Extremities | 1 | 2021 | 130 | 0.170 |
Why?
| | Follow-Up Studies | 2 | 2021 | 5139 | 0.160 |
Why?
| | Vasodilation | 1 | 2003 | 494 | 0.160 |
Why?
| | Cause of Death | 1 | 2021 | 431 | 0.150 |
Why?
| | Subacute Care | 1 | 2019 | 77 | 0.150 |
Why?
| | Brain Ischemia | 1 | 2021 | 341 | 0.140 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2018 | 66 | 0.140 |
Why?
| | Nursing Homes | 1 | 2019 | 167 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2021 | 2066 | 0.140 |
Why?
| | Health Services Research | 1 | 2019 | 403 | 0.130 |
Why?
| | Hospital Mortality | 1 | 2021 | 902 | 0.130 |
Why?
| | Aged | 11 | 2024 | 23798 | 0.130 |
Why?
| | Lipoproteins, LDL | 1 | 1996 | 119 | 0.120 |
Why?
| | Skilled Nursing Facilities | 1 | 2017 | 131 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1465 | 0.110 |
Why?
| | Insulin Resistance | 3 | 2013 | 1198 | 0.110 |
Why?
| | Fibrinolytic Agents | 1 | 2017 | 275 | 0.110 |
Why?
| | Ethics, Research | 1 | 2014 | 32 | 0.110 |
Why?
| | Consensus | 1 | 2017 | 685 | 0.110 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2024 | 2521 | 0.100 |
Why?
| | Anticoagulants | 3 | 2023 | 665 | 0.100 |
Why?
| | Disease Management | 1 | 2017 | 625 | 0.100 |
Why?
| | Societies, Medical | 1 | 2017 | 820 | 0.100 |
Why?
| | Stroke | 1 | 2021 | 1129 | 0.100 |
Why?
| | Caspase 1 | 1 | 2013 | 143 | 0.100 |
Why?
| | Cardiovascular Diseases | 2 | 2021 | 2113 | 0.090 |
Why?
| | Interleukin-18 | 1 | 2013 | 237 | 0.090 |
Why?
| | Interleukin-1beta | 1 | 2013 | 373 | 0.090 |
Why?
| | Heparin | 2 | 2023 | 259 | 0.090 |
Why?
| | Research Design | 1 | 2017 | 1116 | 0.080 |
Why?
| | Biomedical Research | 1 | 2017 | 689 | 0.080 |
Why?
| | Arteries | 2 | 2022 | 269 | 0.080 |
Why?
| | Dietary Fats | 2 | 2010 | 301 | 0.080 |
Why?
| | Lactones | 1 | 2010 | 56 | 0.080 |
Why?
| | Transfection | 2 | 2010 | 948 | 0.080 |
Why?
| | Myoblasts | 1 | 2010 | 84 | 0.080 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2010 | 37 | 0.080 |
Why?
| | Diet, Fat-Restricted | 2 | 2010 | 79 | 0.080 |
Why?
| | Hypercholesterolemia | 1 | 2010 | 105 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 2 | 2021 | 892 | 0.070 |
Why?
| | Obesity | 2 | 2013 | 2974 | 0.070 |
Why?
| | Inflammation | 2 | 2023 | 2837 | 0.070 |
Why?
| | Blotting, Western | 1 | 2010 | 1227 | 0.070 |
Why?
| | Palliative Care | 1 | 2014 | 738 | 0.070 |
Why?
| | Simvastatin | 1 | 2006 | 61 | 0.060 |
Why?
| | Temperance | 1 | 2005 | 13 | 0.060 |
Why?
| | Adult | 5 | 2021 | 37821 | 0.060 |
Why?
| | Anticholesteremic Agents | 1 | 2006 | 153 | 0.060 |
Why?
| | Treatment Failure | 1 | 2005 | 353 | 0.060 |
Why?
| | Cell Line | 1 | 2010 | 2852 | 0.060 |
Why?
| | Cross-Over Studies | 2 | 2006 | 561 | 0.060 |
Why?
| | Weight Loss | 1 | 2010 | 770 | 0.060 |
Why?
| | C-Reactive Protein | 1 | 2006 | 411 | 0.050 |
Why?
| | Incidence | 2 | 2021 | 2792 | 0.050 |
Why?
| | Heart Failure | 1 | 2017 | 2222 | 0.050 |
Why?
| | Thromboplastin | 1 | 2023 | 74 | 0.050 |
Why?
| | Angiography | 1 | 2024 | 209 | 0.050 |
Why?
| | Forearm | 1 | 2003 | 120 | 0.050 |
Why?
| | Vesicular Transport Proteins | 1 | 2003 | 84 | 0.050 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 442 | 0.050 |
Why?
| | Numbers Needed To Treat | 1 | 2021 | 7 | 0.050 |
Why?
| | Metabolic Syndrome | 1 | 2005 | 354 | 0.050 |
Why?
| | Frailty | 1 | 2024 | 169 | 0.050 |
Why?
| | Fasting | 1 | 2003 | 275 | 0.040 |
Why?
| | Postmenopause | 1 | 2003 | 361 | 0.040 |
Why?
| | Regional Blood Flow | 1 | 2003 | 474 | 0.040 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2021 | 190 | 0.040 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2003 | 446 | 0.040 |
Why?
| | Internationality | 1 | 2020 | 155 | 0.040 |
Why?
| | Atherosclerosis | 1 | 2024 | 415 | 0.040 |
Why?
| | Lipid Metabolism | 1 | 2003 | 511 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2003 | 599 | 0.040 |
Why?
| | Confidentiality | 1 | 2019 | 71 | 0.040 |
Why?
| | Alcohol Drinking | 1 | 2005 | 824 | 0.040 |
Why?
| | Acute Disease | 1 | 2021 | 1008 | 0.040 |
Why?
| | Algorithms | 1 | 2006 | 1702 | 0.040 |
Why?
| | Mice | 3 | 2013 | 17843 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1263 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2006 | 1580 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 386 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1241 | 0.030 |
Why?
| | Proteins | 1 | 2003 | 1012 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2003 | 1167 | 0.030 |
Why?
| | Arteriosclerosis | 1 | 1996 | 88 | 0.030 |
Why?
| | Cholesterol, LDL | 2 | 2010 | 366 | 0.030 |
Why?
| | Patient Safety | 1 | 2019 | 305 | 0.030 |
Why?
| | Risk Factors | 2 | 2022 | 10356 | 0.030 |
Why?
| | Particle Size | 1 | 1996 | 394 | 0.030 |
Why?
| | Reference Values | 1 | 1996 | 821 | 0.030 |
Why?
| | Patient Transfer | 1 | 2017 | 165 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 1996 | 344 | 0.030 |
Why?
| | Ethics Committees, Research | 1 | 2014 | 41 | 0.030 |
Why?
| | Animals | 3 | 2013 | 37011 | 0.030 |
Why?
| | Research Personnel | 1 | 2014 | 170 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2024 | 7593 | 0.020 |
Why?
| | Diet, High-Fat | 1 | 2013 | 248 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 5730 | 0.020 |
Why?
| | Diet, Reducing | 1 | 2010 | 88 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7598 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2010 | 153 | 0.020 |
Why?
| | Body Weight | 1 | 2013 | 973 | 0.020 |
Why?
| | Quality Improvement | 1 | 2017 | 1161 | 0.020 |
Why?
| | Communication | 1 | 2014 | 874 | 0.020 |
Why?
| | Phenotype | 1 | 1996 | 3205 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 2074 | 0.020 |
Why?
| | Energy Intake | 1 | 2010 | 478 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2013 | 3020 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2003 | 15628 | 0.010 |
Why?
| | Dyslipidemias | 1 | 2006 | 177 | 0.010 |
Why?
| | Munc18 Proteins | 1 | 2003 | 24 | 0.010 |
Why?
| | SNARE Proteins | 1 | 2003 | 39 | 0.010 |
Why?
| | Time Factors | 1 | 2013 | 6817 | 0.010 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2003 | 216 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 765 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 974 | 0.010 |
Why?
| | Insulin | 1 | 2010 | 2398 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2003 | 2182 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2003 | 4206 | 0.010 |
Why?
| | Blood Glucose | 1 | 2003 | 2183 | 0.010 |
Why?
|
|
Capell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|